EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
- DOI
- 10.1016/j.esmoop.2026.107700
- Published
- 2026 Jun
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.107700,
title = {EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.},
author = {Rosenberg JE and O'Donnell PH and Petrylak DP and Flaig TW and Hoimes CJ and Gupta S and Mar N and Friedlander TW and Tagawa ST and Bilen MA and Brown JR and McKay RR and Merchan JR and Srinivas S and Gorla S and Moreno BH and Davis G and Wirtz HS and Zhu Y and Milowsky MI},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2026.107700},
url = {https://doi.org/10.1016/j.esmoop.2026.107700}
}RIS
TY - JOUR TI - EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. AU - Rosenberg JE AU - O'Donnell PH AU - Petrylak DP AU - Flaig TW AU - Hoimes CJ AU - Gupta S AU - Mar N AU - Friedlander TW AU - Tagawa ST AU - Bilen MA AU - Brown JR AU - McKay RR AU - Merchan JR AU - Srinivas S AU - Gorla S AU - Moreno BH AU - Davis G AU - Wirtz HS AU - Zhu Y AU - Milowsky MI PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2026.107700 UR - https://doi.org/10.1016/j.esmoop.2026.107700 ER -
APA
JE, R., PH, O., DP, P., TW, F., CJ, H., S, G., N, M., TW, F., ST, T., MA, B., JR, B., RR, M., JR, M., S, S., S, G., BH, M., G, D., HS, W., Y, Z., & MI, M. (2026). EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.107700
Source records
- pubmed · retrieved 2026-09-27T07:49:41.251Z